公开(公告)号：US20200155566A1

公开(公告)日：2020-05-21

申请号：US16632954

申请日：2018-08-01

Applicant: Novartis AG

Inventor： Susan Moody ,  Iain Mulford ,  Jordi Barretina

IPC: A61K31/55 ,  A61P35/00 ,  A61K31/519

Abstract: This invention relates to a pharmaceutical combination comprising (a) a third generation EGFR tyrosine kinase inhibitor and (b) a cyclin D kinase 4/6 (CDK4/6) inhibitor, particularly for use in the treatment of a cancer, particularly a lung cancer. This invention also relates to uses of such a combination for the preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.